Page 58 - MemoriaEHD-Eng

RESEARCH GROUPS

ó

í
éé
á

ó
í
ó

ó

PROGRAMME:
Liver Cancer and Cancer G0005

of the Digestive System

Group Members
Lead Researcher

STAFF MEMBERS
Bruix Tudó, Jordi

Boix Ferrero, Loreto
Lpez Oliva, J. Manuel
Contact:
Martnez Quetglas, Iris
Hospital Clinico y Provincial de Barcelona. Peix Gallofre, Judit

C/ Villarroel, 170. Barcelona · Phone: (+34) 93 227 98 03. Prez Pons, Nuria
E.mail: [email protected] · Website: www.bclc.cat
Reig Monzn, Ma Elisa
Rengel Gelada, Ingrid

Main lines of research
ASSOCIATED MEMBERS
Ayuso Colella, Ma Carmen
This group known as the BCLC group is devoted to clinical and translational research
Bianchi Cardona, Luis in liver cancer. The activity may be divided in two major fields that are tightly related:
Bru Saumell, Concepci
clinical research and molecular profiling. As a referral group it maintains an intense
Forner Gonzlez, Alejandro clinical activity that allows running studies including from epidemiology to diagnosis,
Fuster Obregn, Josep
prognosis and treatment. The creation of a tissue collection and the organization of
Llovet Bayer, Josep Ma
Real Mart, Ma Isabel an International Genomic Consortium with other institutions from abroad (Mount
Sinai Medical School in New York, Harvard University, Institute Nationale di Tumori
Sol Arques, Manel
di Milan) has facilitated several investigations to expand the knowledge of the onco-
Vilana Puig, Ramon
genic mechanisms, the proposal of a molecular classification for liver cancer and the

identification of potential novel targets.

The BCLC group has received wide international recognition for its work at all levels.
At the clinical level the group established the relevance of hepatitis C virus infection 13
20
as a risk factor for liver cancer, defined the imaging criteria for imaging diagnosis T
of liver cancer, defined the role of portal pressure measurement in the selection of R
PO
candidates for surgery, established the benefits of ablation for early stage cancers E
and more importantly, demonstrated the benefit of chemoembolization and sorafenib L R
A
through phase 3 randomised trials. Currently, the group leads international research NU
in phase 1, 2 and 3, evaluating various molecular therapies in first or second line and N
A
as adjuvant after surgical resection or chemoembolization.
/
HD
Furthermore, the BCLC strategy for prognosis assessment and treatment allocation E
has been endorsed by major scientific associations and research consortia. The BCLC ER
IB
contributions have laid the foundation for the development of international practice C
guidelines based on scientific evidence as done by EASL, AASLD, WGO, ESMO and
58
ILCA. Indeed, most guidelines have been lead by BCLC investigators.